Recent Company News

• 11:53 AM ET Dec 16, 2025
  

  Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

• 06:14 PM ET Dec 11, 2025
  

  Mesoblast notes independent study concludes that remestemcel-L showed superior outcomes compared to ruxolitinib as treatment for SR-aGvHD (A$2.76, +0.02)

• 07:46 PM ET Nov 26, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 12:48 PM ET Dec 04, 2025
  

  Transcript Intelligence: Mesoblast at Piper Sandler Healthcare Conference (A$2.54, 0.00)

• 10:14 PM ET Nov 25, 2025
  

  StreetAccount Scorecard - Australian ASX200 short interest as at 20-Nov